Salute e Benessere

Monthly information related to total number of voting rights and shares…

Article 223-16 of general regulation of French Autorité des Marchés FinanciersListing market: Euronext Paris (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM)Website : www.phaxiam.com DateTotal of shares composing the share capitalTotal of brut(1)voting rightsTotal of net(2)voting rights December 31, 20236 075 1056 226 9826 226 733January 31, 20246 075 1056 227 0026 226 753February 29, 20246 075 1056...
Nasdaq GlobeNewswire
03/05/2024

Computer Vision in Healthcare Market Worth $11.5 billion | MarketsandMarkets™

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231790940 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231790940 Browse in-depth TOC on "Computer Vision in Healthcare Market" 505 - Tables 55 - Figures 379 - Pages Computer Vision in Healthcare Market Scope: "The largest share in the computer vision in healthcare market, based on type, was attributed to the PC-based computer...
PR Newswire
03/05/2024

PCI Biotech Holding ASA - Notice of Annual General Meeting 2024

The notice and proposed resolutions to the annual general meeting are attached. The notice, including all appendices, will be made available at PCI Biotech's corporate websitewww.pcibiotech.com.For further information, please contact: Ronny Skuggedal, CEO/CFO, E-mail: rs@pcibiotech.no Office: +47 67 11 54 00 Mobile: +47 94 00 57 57This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachments PCI Biotech...
Nasdaq GlobeNewswire
03/05/2024

Nexstim, Inc. and Inomed Inc. Enter into Strategic Alliance Agreement for US…

Press release, Helsinki, 3 May 2024, 10 AM (EEST) Nexstim, Inc. and Inomed Inc. Enter into Strategic Alliance Agreement for US Market Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that Nexstim, Inc. has signed a non-exclusive strategic alliance agreement with Inomed Inc. for the purpose of strengthening the collaboration of Marketing, Sales, and Application Support between both companies in the United States.Both Nexstim and Inomed will attend the American…
Nasdaq GlobeNewswire
03/05/2024

Hansa Biopharma: increase in number of shares and votes

The information in the press release is information that Hansa Biopharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons above, on May 3, 2024 at 08:00 (CEST). The information in the press release is information that Hansa Biopharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the...
PR Newswire
03/05/2024

Q1 update: Novonesis delivers 4% organic sales growth in line with expectations…

For the first quarter as Novonesis, the company delivers 4% organic sales growth in line with expectations. Novonesis maintains the 2024 outlook of 5-7% organic sales growth with an adjusted EBITDA margin of around 35%. COPENHAGEN, Denmark – May 3, 2024.In the first three months of the 2024 financial year, Novonesis delivers 4% organic sales growth against a strong comparator. The organic sales growth in the first quarter is driven by both Food & Health Biosolutions and Planetary...
Nasdaq GlobeNewswire
03/05/2024

Trading statement Q1 2024

Novonesis realized 4% organic sales growth in line with expectations and maintains 2024 outlook. Ester Baiget, President & CEO:“I am pleased with the first quarter organic sales growth of 4% with growth in both Food & Health and Planetary Health. We are off to a good start in line with expectations and very well on track to deliver 5-7% organic sales growth for the full year with an adjusted EBITDA margin of around 35%. It's highly comforting to see our new organization's focus on...
Nasdaq GlobeNewswire
03/05/2024

Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID…

Allschwil, Switzerland, May 03, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that scientific presentations with new data on its antibiotic ceftobiprole (Zevtera ® ) have been presented at ESCMID Global 2024, the annual meeting of the European Society of Clinical Microbiology and Infectious Diseases, which took place from April 27 to 30,...
Nasdaq GlobeNewswire
03/05/2024

Muscle Stimulator Market Projected to Reach $925.48 million by 2030 - Exclusive…

The demand for muscle stimulators is witnessing a remarkable upswing worldwide, significantly influenced by a growing focus on physical fitness and a noticeable rise in sports-related injuries. Electrical muscle stimulation (EMS) systems are gaining traction in medical treatments and athletic training known for their role in muscle rehabilitation and strength enhancement through electrical impulses. A key factor driving their popularity is the increasing acknowledgment of their effectiveness…
PR Newswire
03/05/2024

Global Angioplasty Balloons and Stents Market to Exhibit Substantial Growth at a…

Key Takeaways from the Angioplasty Balloons and Stents Market Report Key Takeaways from the Angioplasty Balloons and Stents Market Report To read more about the latest highlights related to the angioplasty balloons and stents market, get a snapshot of the key highlights entailed in theGlobal Angioplasty Balloons and Stents Market Report Angioplasty Balloons and Stents Overview Angioplasty balloons and stents represent groundbreaking advancements in cardiovascular medicine,...
PR Newswire
02/05/2024

Cellectis Appoints Arthur Stril as Interim Chief Financial Officer

Mr. Stril joined Cellectis in 2018 as Vice President, Corporate Development, and was appointed Chief Business Officer in 2020. He has been managing Cellectis' business development and portfolio management teams and most recently led the execution of the Company's strategic collaboration and investment agreements with AstraZeneca. As interim Chief Financial Officer, Mr. Stril will oversee the finance and investor relations functions, and continue to oversee the business development functions...
Nasdaq GlobeNewswire
02/05/2024

Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial…

Reported $420.5 million in cash resources as of March 31, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Completion of rolling biologics license application (BLA) filing with the U.S. Food and Drug Administration (FDA) for zanidatamab as second-line treatment for biliary tract cancers (BTC) in the United States (U.S.) by our partner, Jazz PharmaceuticalsExpected initiation of a Phase 3 clinical trial for...
Nasdaq GlobeNewswire
02/05/2024

Galapagos reports first quarter 2024 financial results  

Advanced potentially best-in-class cell therapy and small molecule R&D pipeline comprising four clinical assets and >15 discovery programs in oncology and immunologyExecuted agreements with BridGene Biosciences and Thermo Fisher Scientific, and investment in Frontier MedicinesTransferred Jyseleca® business to Alfasigma S.p.A., freeing up resources to invest in growth areasGroup net revenues in the first quarter of €100 millionCash and current financial investments of...
Nasdaq GlobeNewswire
02/05/2024

AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB…

PRESS RELEASETHE PARIS COURT OF APPEAL CONFIRMS THE ACQUITTAL OF THE CEO OF AB SCIENCE, ALAIN MOUSSY, AND REDUCES THE AMOUNT OF THE FINANCIAL PENALTY IMPOSED ON AB SCIENCEParis, May 2, 2024, 7pm CETAB Science SA(Euronext - FR0010557264 - AB) and the Chairman of the French market regulator ( Autorité des Marchés Financiers- AMF) had filed an appeal to the Paris Court of Appeal against the decision of the AMF Sanctions commission, dated March 24, 2022, which acquitted Alain...
Nasdaq GlobeNewswire
02/05/2024

Number of voting rights as of April 30, 2024

Nicox SA Société anonyme with a registered capital of € 50,299,694 Head Office: Sundesk Sophia Antipolis, Emerald Square, rue Evariste Galois – 06410 Biot R.C.S. ANTIBES 403.942.642 On May 2 nd, 2024, MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS (Article 223-16 of the General Regulation of the AMF) Market: Euronext Growth ParisISIN Code: FR0013018124 Website:www.nicox.com As of April 30, 2024...
Nasdaq GlobeNewswire
02/05/2024

Crossject signs a geographic extension of ZEPIZURE® commercialization agreement…

Extended contract now covers a total of 11 European countriesCrossject will receive milestone payments of up to €1 million in total, upon marketing authorizationsCrossject will sell ZEPIZURE® to the partner with a markup that is a share of the gross marginDijon, France May 02, 2024 -530 pm CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations,announces it has extended the geographic...
Nasdaq GlobeNewswire
02/05/2024

SIS International Launches Unique Personal Care Products Consulting, Strategy…

"We are excited to introduce our expanded consulting solutions for the personal care products sector. We have a proven track record of supporting leading brands in the industry such as Avon, Colgate-Palmolive, Estee Lauder, Johnson Diversey, L'Oreal, Proctor & Gamble, Revlon, and Shiseido. Our goal is to empower personal care brands with strategic insights and data-driven solutions to drive growth and innovation as we understand the unique challenges and opportunities in the beauty…
PR Newswire
02/05/2024

Genmab Announces Financial Results for the First Quarter of 2024

May 2, 2024 Copenhagen, Denmark;Interim Report for the First Quarter Ended March 31, 2024Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY ®(epcoritamab-bysp) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy, with a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2024...
Nasdaq GlobeNewswire
02/05/2024

Cardiac Monitoring & Cardiac Rhythm Management Devices Market Worth $26.4…

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=55 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=55 Browse in-depth TOC on "Cardiac Monitoring & Cardiac Rhythm Management Devices Market" 424 - Tables 48 - Figures 313 - Pages Cardiac Monitoring & Cardiac Rhythm Management Devices Market Scope: Resting ECG in ECG type segment to witness the highest shares during the...
PR Newswire
02/05/2024

Neurovascular Intervention Devices Market Projected to Reach $6.21 billion by…

Neurovascular disorders, conditions impacting the blood vessels of the brain and nervous system, are at the forefront of medical innovation with the advent of neurovascular intervention devices. Designed for precision, these devices, including stents, embolic coils, and clot retrieval tools, facilitate minimally invasive approaches to treat critical conditions such as aneurysms and strokes, significantly improving patient recovery times and outcomes. The demand for such advanced treatments is on…
PR Newswire
02/05/2024

SPARK™ CLEAR ALIGNERS ANNOUNCES HIGHLY ANTICIPATED "ON-DEMAND" ORDERING PROGRAM

"This unique program will further our doctors' ability to grow their practices by offering an affordable and flexible option to purchase aligners for orthodontic treatment without committing to a certain volume," said Eric Conley, President of Ormco. "We are committed to providing doctors flexibility and choice, both clinically and in how they purchase our products. This solution gives doctors the ability to select the aligner treatment that makes the most sense for their patients…
PR Newswire
02/05/2024

MYONEX CLOSES CREAPHARM ACQUISITION EXPANDING GLOBAL SERVICES

"We are excited to welcome Eric Placet, the visionary founder and former CEO of CREAPHARM, to the Myonex Board of Directors. His decision to reinvest in the company is a testament to our shared commitment to excellence and innovation. Additionally, we are pleased to announce the appointment of Carla Da Costa as our Chief Operating Officer, further strengthening our executive team as we continue to drive growth and deliver exceptional value to our clients," stated Mike Cohen, Executive…
PR Newswire
02/05/2024

KFSH&RC Ranked Top Valuable Healthcare Brand in Saudi Arabia and Middle East

thin Saudi Arabia and 28 thin the Middle East. Additionally, KFSH&RC stands out as the only hospital worldwide to be ranked among its country's top ten most valuable brands.The Brand Finance Report shows that KFSH&RC brand value increased by 31%, exceeding 5.6 billion Saudi Riyals, equivalent to USD 1.5 billion. This increase is the result of the hospital's unwavering commitment to incorporating the latest medical technologies and treatments and providing specialized medical...
Nasdaq GlobeNewswire
02/05/2024

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

The Company anticipates filing the Required Annual Filings and the Required Interim Filings by May 13, 2024. As previously disclosed, the auditor of the Company requires additional time to complete its audit of the Company, including the Company's recent acquisition of all intellectual property, immunotherapeutics platform Technology, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. The Company is working with its auditor in order to file the Required Annual…
PR Newswire
02/05/2024
Altri  Comunicati